Bristol Myers Squibb scored a confirmatory trial win for Krazati, the KRAS inhibitor it picked up earlier this year through its $4.8 billion acquisition of Mirati.
In December 2022, Krazati won an accelerated approval for non-small cell lung cancer patients, becoming the second approved KRAS…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
